Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)

Mark A. Baxter (Lead / Corresponding author), Russell D. Petty, Daniel Swinson, Peter S. Hall, Shane O'Hanlon

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
33 Downloads (Pure)


Gastroesophageal adenocarcinoma (GOA) is a disease of older people. Incidence is rising in the developed world and the majority of patients present with advanced disease. Based on clinical trial data, systemic chemotherapy in the advanced setting is associated with improvements in quality of life and survival. However, there is a recognised mismatch between trial populations and the patients encountered in clinical practice in terms of age, comorbidity and fitness. Appropriate patient selection is essential to safely deliver effective treatment. In this narrative review, we discuss the challenges faced by clinicians when assessing real‑world patients with advanced GOA for systemic therapy. We also highlight the importance of frailty screening and the current available evidence we can use to guide our management.

Original languageEnglish
Article number22
Pages (from-to)1-13
Number of pages13
JournalInternational Journal of Oncology
Issue number5
Early online date17 Mar 2021
Publication statusPublished - May 2021


Dive into the research topics of 'Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)'. Together they form a unique fingerprint.

Cite this